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Since Albright, [1] some 60 years ago, reported the benefi-
cial effects of estrogens for decreasing urinary calcium ex-
cretion and suggested that these harmones might be useful
in preventing postmenopausal osteoporosis, estrogen re-
placement therapy (ERT) has been consistently regarded as
the first choice for prevention of trabecular and cortical
bone loss in postmenopausal women [2–5]. However, seri-
ous controversies remain over the cost/effectiveness of
treating every woman at the time of menopause [6], the
optimal timing for starting ERT [5], the minimal effective
dose of ERT acting on bone [7], and the duration of ERT
needed to prevent osteoporotic fractures [8]. The effective-
ness of ERT for preventing osteoporosis-related fractures is
undisputed and requirements for marketing authorization
for ERT products have lightened compared with current
requests for other therapeutic medications developed in this
field [9, 10]. However, although the skeletal benefits of
ERT for preventing trabecular or cortical bone loss can
hardly be challenged, one might be wary of published evi-
dence that prolonged ERT use unequivocally reduces the
risk of hip fracture. Controlled clinical trials and systematic
reviews were located using Medline 1970–1999 and
EMBASE 1980–1999. Since 1985 we have searched scien-
tific journals on bone and bibliographies of review articles.
All prospective controlled trials were included for evalua-
tion of the effects of hormone replacement therapy (HRT)
on bone loss. A total of 57 prospective controlled trials were
identified, 46 of which were randomized clinical trials
(RCTs) and 15 were double blinded. All clinical trials as-
sessing the effects of HRT on fracture rates were consid-
ered. Two RCTs and one systematic review were identified
[11].
In the 46 randomized controlled trials comparing estro-
gen (with or without progestins) (HRT) with placebo or
calcium on bone loss prevention, the study population var-
ied from 14 to 875 women and the duration was from .5 to
10 years. In general, they drew similar conclusions, i.e, that
estrogen intervention reduces the rate of postmenopausal
bone loss at trabecular and cortical sites. An early double-
blind trial [12] reported the preventive effects of HRT on
cortical (metacarpal) bone loss for up to 10 years. More
recent double-blind, placebo-controlled, randomized clini-
cal trials confirmed these findings for oral [13], percutane-
ous [14, 15], or transdermal [16] estrogens at the spine [13,
14, 16], the forearm [16], and/or the hip [13, 16] for up to
3 years. Two prospective open studies [17, 18] showed
similar results for estrogen implants after 1 year. When
standardized for technique used for bone mineral density
(BMD) assessment, the magnitude of the point estimate
differences between the HRT and the control group varied
greatly from one study to another, depending upon the dose
of HRT used (dose-related effect on bone mass in most
Correspondence to: J.-Y. Reginster, CHU Sart Tilman, Bâtiment
B23, 4000 Liège, Belgique
Calcif Tissue Int (2000) 67:191–194
DOI: 10.1007/s002230001135
© 2000 Springer-Verlag New York Inc.
randomized controlled trials), skeletal site measured (effect
more pronounced on trabecular bone), age of the population
(effect more pronounced early after the menopause) [19],
and the nature of the combined progestins (trivial effect of
progestins except for norethisterone acetate that synergisti-
cally acts with estrogens to increase bone mass) [20, 21].
Though evidence that HRT prevents postmenopausal bone
loss is strong, studies providing direct demonstration of a
reduction in fracture rates as a consequence of HRT intake
are more scarce and subject to controversy.
No systematic review has evaluated the effect of HRT on
vertebral fracture rates. In one single, double-blind, ran-
domized, controlled trial [16], 75 postmenopausal women
(47–75 years) with one or more prevalent vertebral frac-
tures, were randomized to transdermal HRT (17b estradiol
and oral medroxyprogesterone acetate) or placebo. After 12
months, 8 new fractures occurred in 7 women in the estro-
gen group whereas 20 occurred in 12 women in the placebo
group, yielding a lower vertebral fracture rate in the estro-
gen group (RR 4 0.39, 95% CI 4 0.16–0.95). However,
these results were based on the number of fractures per
person-years (23 versus 58/100). When expressing the re-
sults as the number of patients having experienced a new
vertebral fracture, as recommended in regulatory guidelines
[10] the difference between 7 women suffering fractures in
HRT and 12 in placebo is no longer statistically significant.
A group of 100 postmenopausal women who had previously
taken part in a randomized controlled trial were reviewed
afer a median follow-up period of 9 years [22]. An indirect
measurement (total spine score) of the prevalence of verte-
bral fracture revealed a significant (P < 0.01) difference in
favor of estrogen users compared with placebo-treated pa-
tients, whereas other indices (absolute difference in anterior
height and ratio of central vertebral height to anterior height
of vertebrae) failed to achieve significance. In a case-control
study published first as a retrospective survey of 490
women followed for an average of 17.6 years [23], and later
as the same cohort followed for an additional average of 8
years [24], RR for vertebral and wrist fractures in estrogen
users were 0.57 (95% CI 4 0.41–0.80) and 0.55 (95% CI
4 0.32–0.92), respectively.
For nonvertebral fractures, one systematic review of the
literature published between 1970 and 1991 is available
[25]. From the analysis 11 epidemiological studies (6 case-
control and 5 cohort), the authors concluded that the pooled
estimates of the relative risk for hip fracture comparing
ever-users of estrogen with nonusers was 0.75 (95% CI 4
0.68–0.84). Since that time, two randomized controlled tri-
als and five epidemiological studies have evaluated the ef-
fect of HRT on nonspinal osteoporotic fractures. A double-
blind, placebo-controlled, randomized trial was primarily
designed to evaluate the effect of HRT on secondary pre-
vention of coronary heart disease, assessment of fractures
being only a secondary endpoint. After following 2763
postmenopausal women younger than 90 years of age for an
average of 4.1 years, the authors found no difference be-
tween estrogen and placebo users for hip fracture (12 in the
HRT group versus 11 in the placebo group) (RR 4 1.10:
95% CI 4 0.49–2.50) or any fracture (RR 4 0.95; 95% CI
4 0.75–1.21) [26].
One can argue that in this study, fracture reduction was
not the primary endpoint, the overall number of hip fracture
was too low to draw significant conclusions, the study was
not powered to assess this outcome, the study population
was not selected on the basis of risk factors for osteoporosis,
and that some doubts remain regarding fracture data collec-
tion. However, the most worrisome fact is not the absence
of significant reduction in hip fractures but that the absolute
number of hip fractures did not even show a trend in favor
of HRT users.
From an open, randomized, controlled trial [27] having
included 464 postmenopausal women, 368 were followed
for a mean duration of 4.3 years. The estimate risk of new
symptomatic nonvertebral fractures among women treated
with HRT alone was 0.29 (95% CI 4 0.10–0.90) whereas
it was nonsignificant in women receiving a combination of
HRT and vitamin D (RR 4 0.44; 95% CI 4 0.17–1.15)
compared with the placebo group (adjusted by femoral den-
sity and previous fractures).
From the five epidemiological studies, three were pro-
spective cohort studies and two retrospective, case-control
trials. In the DUBBO study [28] (1091 women), mean age
70 years, followed prospectively between 1989 and 1993,
the incidence of atraumatic fractures (any site) among non-
estrogen users was not significantly different than that of
estrogen users (OR 4 1.06; 95% CI 4 0.94–1.16).
The follow-up of the Framingham study through exami-
nation 19 (2873 women originally recruited and 948 attend-
ing examination 19) [29] also revealed that current estrogen
intake was not significantly linked to a reduction in hip
fracture (OR 4 0.38; 95% CI 4 0.12–1.21).
More recently, the analysis of the “Study of Osteoporotic
Fracture” (SOF) [15] (9704 women, 65 years of age or
older, followed during an average of 4.6 years) concluded
that current estrogen use was associated with a decrease in
the risk for wrist fracture (RR 4 0.39; 95% CI 4 0.24–
0.64) and for all nonspinal fractures (RR 4 0.66; 95% CI
4 0.54–0.80) when compared with nonestrogen users. The
risk for hip fracture was not significantly different between
current users and never-users (RR 4 0.60; 95% CI 4 0.36–
1.02). However, current users who had started HRT within
5 years of menopause had a decreased risk of hip fracture
(RR 4 0.29; 95% CI 4 0.09–0.92), wrist fracture (RR 4
0.29; 95% CI 4 0.13–0.68), and all nonspinal fractures (RR
4 0.50; 95% CI 4 0.36–0.70). The authors of this pro-
spective cohort study concluded that for protection against
fracture, estrogen should be initiated soon after the meno-
pause and continued indefinitely [8].
The two retrospective case-control studies are the
MEDOS study [30] (2086 women with hip fractures and
3582 controls) and the Swedish hip fracture study [31, 32]
(1328 incident cases with hip fracture and 3312 randomly
selected controls). In the MEDOS study, the relative risk of
hip fracture in women taking estrogen was 0.55 (95% CI 4
0.31–0.85). In the Swedish study, current estrogen users
were significantly protected against hip fracture (OR + 0.35;
95% CI 4 0.24–0.53) whereas no significant difference
was observed for former users (OR 4 0.76; 95% CI 4
0.57–1.01). The protective effect of estrogens was substan-
tially diminished after 5 years of HRT cessation (−7% to
−48%). In view of these results, the problem of long-term
compliance of postmenopausal women with HRT becomes
even more critical.
Several cross-sectional or retrospective studies have ad-
dressed this issue in daily practice. From the SOF cohort
(9704 non-black women aged 65 and older), 17.1% of the
women between 65 and 69 years reported current use of oral
estrogens but only 3.9% of women 85 years and older were
currently using oral estrogens [33]. From the database of the
Kayser Foundation Health Plan [39] (1532 women >45
years old who initially filled index prescription for 0.625
mg/day of conjugated estrogens), the probability of continu-
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ing HRT for 36 months varied between 0.19 (continuous
combined estrogens-progestin therapy) and 0.24 (cyclic
combination therapy adding progestin to estrogens) [40].
Even worse results reported from a survey of five group
practices of Dutch general practitioners (1689 women aged
45–60 years) where the mean duration of HRT use (main
indication for prescription was menopausal complaints) was
7 months and only 8% of the women remained on HRT for
more than 2 years (41). In the United Kingdom (400 post-
menopausal women aged 40–69 years), prescription of HRT
because of increased risk for osteoporosis resulted in 40%
of women with low BMD not taking HRT 8 months after
referral (42). In all surveys, the main reasons for stopping
HRT were anxiety over possible side-effects, especially
breast cancer, weight gain, and bleeding.
The purpose of the present editorial is not to challenge
the overall benefit of HRT in postmenopausal women. Ex-
traskeletal benefits of ERT or HRT have been extensively
discussed elsewhere. (see 43). Our concern is the preferen-
tial treatment given to HRT products compared with other
currently developed medications, where evidence of an an-
tifracture efficacy at the level of the spine or hip is re-
quested. We are convinced that if any new chemical entity
other than the one currently available for ERT or HRT, i.e.,
bisphosphonates, calcitonin, or SERMS, were filing for
marketing authorization with such a limited demonstration
of antifracture efficacy it would most likely be poorly re-
ceived both by regulatory authorities and the scientific com-
munity.
We agree that initiating a double-blind, placebo-
controlled prospective study evaluating the antifracture ben-
efit of HRT on the spine or the hip would not only be a
methodological challenge but also somewhat unethical in
view of the extraskeletal benefits of HRT. However, in view
of appropriate published studies demonstrating the antifrac-
ture efficacy of antiosteoporotic drugs, an open prospective
equivalent trial comparing HRT to these drugs, with spine
or hip fracture reduction as a primary endpoint, would sci-
entifically validate the currently widespread dogma that
HRT should be used for life by postmenopausal women to
prevent osteoporosis-related fractures.
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